News

Our Way

 

TolerogenixX will innovate immunosuppression with its newly developed MIC cell treatments.

MIC cell treatment is a curative ATMP approach to achieve a sustained regulation of the immune system in transplanted and autoimmune patients.

Since our first steps in 2015 and the foundation of TolerogenixX GmbH in 2016, we have never tired of fighting for our idea of personalized immune modulation.



January 2020 - Publication

TolerogenixX publishes the TOL-1 Study in Journal of Clinical Investigation

November 2019 - Investment

TolerogenixX closes a financing round with several investors in the amount of € 4.1 million

November 2019 - ASN

TolerogenixX was invited to present the preclinical SLE data at the Annual congress of the American Society of Nephrology in Washington

October 2019 - DTG Lecture

TolerogenixX was invited for a lecture at the Annual Meeting of the Germany Transplant Society in Hannover

October 2019 - DGfN Lecture

TolerogenixX was selected to give a talk at the Annual Meeting of the German Society of Nephrology

September 2019 - Biotech Forum

TolerogenixX participates at the 19th Annual Biotech in Europe Forum in Basel

September 2019 - Science Award

The preclinical results of the SLE mouse model were awarded with the science prize of the German Society of Rheumatology

June 2019 - EULAR

TolerogenixX gave a talk to the benefit of MIC therapy in a murine SLE mouse model at the EULAR congress in Madrid

June 2019 - ERA-EDTA

TolerogenixX presented the SLE mouse model data at the ERA-EDTA Congress in Budapest

May 2019 - Posterprize

TolerogenixX was awarded at the German Society for Internal Medicine for the best poster

May 2019 - New IP

TolerogenixX filed new IP in the field of organ transplantation

April 2019 - Lupus 2019

TolerogenixX presented the preclinical SLE data during an oral presentation at the Lupus 2019 Congress in San Francisco

April 2019 - Pitch

TolerogenixX was selected to pitch at the start-up session of the Meeting of the nationwide DIHK committee for health sciences

April 2019 - German Biotechnology Days

TolerogenixX participated in the Start-up Meeting of the German Biotechnology Days in Würzburg

April 2019 - Cell and Gene

Participation at the Cell and Gene Congress in Barcelona

March 2019 - World Pharma Pricing and Market Access

Participation and Chairing of a session at the World Pharma Pricing and Market Access meeting in Amsterdam

February 2019 - Pitch

TolerogenixX was invited for a pitch in the rising star session of the 12TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM in Zürich

November 2018 - Results of TOL-1 study

TolerogenixX reported the results of the TOL-1 study at the annual nephrological meeting of the Association of German Renal Centers

November 2018 - Day of Internal Rheumatology

TolerogenixX presented the MIC therapy and its potential for the treatment of autoimmune diseases at the Day of Internal Rheumatology in Heidelberg

November 2018 - Resultate der TOL-1 Studie auf der DTG

TolerogenixX presented the results of the TOL-1 study as an invited presentation at Annual Conference of the German Transplantation Society

October 2018 - Results of TOL-1 Study at ASN

TolerogenixX presented the results of the TOL-1 study on tolerance induction in kidney transplant patients during an oral presentation at the ASN annual congress and this contribution was selected by NephroToday as a congress highlight

October 2018 - Pitch

TolerogenixX was selected to a pitch presentation at the Investment Forum of the Federal Ministry of Economics in Berlin

Otober 2018 - Quality assessment

TolerogenixX gave a talk to “Induction of donor-specific immunomodulation by clinical MIC cell infusion – a phase I study (TOL-1)” at the annual congress of the German, Austrian and Suisse Society of Hematology and Medical Oncology in Vienna.

 

 

September 2018 - Swiss Start-up Days

TolerogenixX visited the Swiss Start-up Days

September 2018 - Best Abstract Prize

TolerogenixX was invited to present the clinical results of the TOL-1 Study at the Annual Congress of the German Society of Rheumatology

September 2018 - Resultate der TOL-1 Studie

TolerogenixX was invited to present the clinical results of the TOL-1 Study at the Annual Congress of the German Society of Rheumatology

June 2018 - Lecture

TolerogenixX was selected to give a lecture at the American Transplant Congress in Seattle

May 2018 - Resultate der TOL-1 Studie auf der 55. ERA-EDTA

TolerogenixX presented the results of the TOL-1 study as an oral presentation at the ERA-EDTA congress in Copenhagen

February 2018 - Venture Capital Pitch

TolerogenixX becomes 2nd winner of the Best of Baden-Württemberg Venture Capital Pitch, 1st winner for the life science sector

TOLEROGENIxX PD Dr. Matthias Schaier, MBA - 7. Venture Capital Pitch

click play

September 2017 - Science Sparks

TolerogenixX takes part in a panel discussion on the topic „Inspirational Stories from Seasoned Entrepreneurs and Newcomers together with their investors“

September 2017 - Business Development

TolerogenixX was selected to give a company presentation at the European Business Development Conference in Heidelberg

June 2017 - EXIST II

TolerogenixX receives funding (Exist II) from the Federal Ministry of Economic Affairs and Energy (BMWi)

May 2017 - HTGF Pitch

TolerogenixX pitches at the HTGF Family Day 2017

March 2017 - Investment Forum

TolerogenixX was invited to a company presentation at the Investment Forum of the Federal Ministry of Economics in Berlin

December 2016 - Seeding Phase

The High-Tech Gründerfonds (HTGF) invests in TolerogenixX GmbH as a seed investor

December 2016 - Founding

GmbH Founding

Award for the 1st prize-winners of the Venture Cup 2015

28. July 2015

The science4Life e.V. office is pleased to announce the Tolerogenixx-Team as the winners of the Venture Cup 2015 and to officially hand over the seal of quality to them.    

Science4Life e.V.

July 2015 - Business Plan

TolerogenixX wins 1st place in the Science4Life business plan competition

1st prize at the Science 4 Life Venture Cup 2015

14. July 2015

Frankfurt am Main (ots) - TolerogenixX from Heidelberg wins with a therapy that significantly improves the quality of life of organ transplanted patients   

The founders of Science4Life e. V. the signs point to success: 

The patrons, the Hessian Minister of Economic Affairs Tarek Al-Wazir and Prof. Dr. Jochen Maas, Research Director of Sanofi-Aventis Deutschland GmbH, were delighted with the record number of business ideas submitted and praised the ten best founding teams for their innovative ideas and entrepreneurial courage.   

At the final award ceremony at the Deutsche Bundesbank's head office, the winning teams received not only plenty of praise but also prize money totalling 56,000 euros. The first prize was awarded to TolerogenixX for the development of a tailored therapy without side effects in transplantation and for patients with autoimmune diseases.

press report

logo